nodes	percent_of_prediction	percent_of_DWPC	metapath
Solifenacin—Benazepril—Ramipril—type 2 diabetes mellitus	0.336	1	CrCrCtD
Solifenacin—CYP3A4—type 2 diabetes mellitus	0.202	1	CbGaD
Solifenacin—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0314	0.152	CbGbCtD
Solifenacin—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.028	0.136	CbGbCtD
Solifenacin—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0256	0.124	CbGbCtD
Solifenacin—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0224	0.109	CbGbCtD
Solifenacin—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0203	0.0982	CbGbCtD
Solifenacin—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0154	0.0744	CbGbCtD
Solifenacin—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0147	0.0713	CbGbCtD
Solifenacin—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0147	0.0713	CbGbCtD
Solifenacin—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0139	0.0675	CbGbCtD
Solifenacin—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0104	0.0503	CbGbCtD
Solifenacin—CYP3A4—Losartan—type 2 diabetes mellitus	0.00949	0.046	CbGbCtD
Solifenacin—Benazepril—MTHFR—type 2 diabetes mellitus	0.00112	0.473	CrCbGaD
Solifenacin—Benazepril—ACE—type 2 diabetes mellitus	0.00091	0.386	CrCbGaD
Solifenacin—Mequitazine—CYP3A4—type 2 diabetes mellitus	0.000332	0.141	CrCbGaD
Solifenacin—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000185	0.00101	CcSEcCtD
Solifenacin—Infection—Gliclazide—type 2 diabetes mellitus	0.000184	0.00101	CcSEcCtD
Solifenacin—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000184	0.00101	CcSEcCtD
Solifenacin—Erythema multiforme—Losartan—type 2 diabetes mellitus	0.000184	0.00101	CcSEcCtD
Solifenacin—Palpitations—Orlistat—type 2 diabetes mellitus	0.000183	0.001	CcSEcCtD
Solifenacin—Cough—Valsartan—type 2 diabetes mellitus	0.000182	0.001	CcSEcCtD
Solifenacin—Renal failure—Ramipril—type 2 diabetes mellitus	0.000182	0.001	CcSEcCtD
Solifenacin—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000182	0.001	CcSEcCtD
Solifenacin—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000182	0.001	CcSEcCtD
Solifenacin—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000182	0.001	CcSEcCtD
Solifenacin—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000181	0.000996	CcSEcCtD
Solifenacin—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00018	0.000991	CcSEcCtD
Solifenacin—Urinary tract infection—Ramipril—type 2 diabetes mellitus	0.00018	0.000991	CcSEcCtD
Solifenacin—Cough—Orlistat—type 2 diabetes mellitus	0.00018	0.00099	CcSEcCtD
Solifenacin—Asthenia—Glimepiride—type 2 diabetes mellitus	0.00018	0.000988	CcSEcCtD
Solifenacin—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.00018	0.000988	CcSEcCtD
Solifenacin—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.00018	0.000987	CcSEcCtD
Solifenacin—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.00018	0.000987	CcSEcCtD
Solifenacin—Vision blurred—Metformin—type 2 diabetes mellitus	0.000179	0.000986	CcSEcCtD
Solifenacin—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000179	0.000985	CcSEcCtD
Solifenacin—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000179	0.000982	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000179	0.000981	CcSEcCtD
Solifenacin—Dizziness—Glipizide—type 2 diabetes mellitus	0.000178	0.000976	CcSEcCtD
Solifenacin—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000177	0.000975	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000177	0.000971	CcSEcCtD
Solifenacin—Angiopathy—Losartan—type 2 diabetes mellitus	0.000176	0.000968	CcSEcCtD
Solifenacin—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000176	0.000966	CcSEcCtD
Solifenacin—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	0.000175	0.000964	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000175	0.000959	CcSEcCtD
Solifenacin—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000174	0.000956	CcSEcCtD
Solifenacin—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000172	0.000945	CcSEcCtD
Solifenacin—Vomiting—Glipizide—type 2 diabetes mellitus	0.000171	0.000939	CcSEcCtD
Solifenacin—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.000171	0.000937	CcSEcCtD
Solifenacin—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.00017	0.000936	CcSEcCtD
Solifenacin—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00017	0.000935	CcSEcCtD
Solifenacin—Infection—Valsartan—type 2 diabetes mellitus	0.000169	0.000931	CcSEcCtD
Solifenacin—Rash—Glipizide—type 2 diabetes mellitus	0.000169	0.000931	CcSEcCtD
Solifenacin—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000169	0.00093	CcSEcCtD
Solifenacin—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000169	0.00093	CcSEcCtD
Solifenacin—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000169	0.000929	CcSEcCtD
Solifenacin—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000169	0.000926	CcSEcCtD
Solifenacin—Headache—Glipizide—type 2 diabetes mellitus	0.000168	0.000925	CcSEcCtD
Solifenacin—Palpitations—Metformin—type 2 diabetes mellitus	0.000168	0.000924	CcSEcCtD
Solifenacin—Infection—Orlistat—type 2 diabetes mellitus	0.000167	0.00092	CcSEcCtD
Solifenacin—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000167	0.000919	CcSEcCtD
Solifenacin—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000166	0.000911	CcSEcCtD
Solifenacin—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000166	0.00091	CcSEcCtD
Solifenacin—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000166	0.00091	CcSEcCtD
Solifenacin—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000165	0.000908	CcSEcCtD
Solifenacin—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000165	0.000908	CcSEcCtD
Solifenacin—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000165	0.000907	CcSEcCtD
Solifenacin—Hypertension—Metformin—type 2 diabetes mellitus	0.000164	0.000903	CcSEcCtD
Solifenacin—Urticaria—Glyburide—type 2 diabetes mellitus	0.000164	0.000903	CcSEcCtD
Solifenacin—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000164	0.000902	CcSEcCtD
Solifenacin—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000164	0.000901	CcSEcCtD
Solifenacin—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000164	0.0009	CcSEcCtD
Solifenacin—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000164	0.000899	CcSEcCtD
Solifenacin—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000163	0.000898	CcSEcCtD
Solifenacin—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000163	0.000898	CcSEcCtD
Solifenacin—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000162	0.000892	CcSEcCtD
Solifenacin—Headache—Pioglitazone—type 2 diabetes mellitus	0.000161	0.000886	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000161	0.000884	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00016	0.000881	CcSEcCtD
Solifenacin—Fatigue—Gliclazide—type 2 diabetes mellitus	0.00016	0.00088	CcSEcCtD
Solifenacin—Nausea—Glipizide—type 2 diabetes mellitus	0.00016	0.000877	CcSEcCtD
Solifenacin—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000159	0.000876	CcSEcCtD
Solifenacin—Vision blurred—Losartan—type 2 diabetes mellitus	0.000159	0.000875	CcSEcCtD
Solifenacin—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000159	0.000873	CcSEcCtD
Solifenacin—Constipation—Gliclazide—type 2 diabetes mellitus	0.000159	0.000872	CcSEcCtD
Solifenacin—Rash—Glimepiride—type 2 diabetes mellitus	0.000158	0.000869	CcSEcCtD
Solifenacin—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000158	0.000868	CcSEcCtD
Solifenacin—Rash—Sitagliptin—type 2 diabetes mellitus	0.000158	0.000866	CcSEcCtD
Solifenacin—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000157	0.000865	CcSEcCtD
Solifenacin—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000157	0.000865	CcSEcCtD
Solifenacin—Headache—Glimepiride—type 2 diabetes mellitus	0.000157	0.000863	CcSEcCtD
Solifenacin—Cough—Irbesartan—type 2 diabetes mellitus	0.000157	0.000861	CcSEcCtD
Solifenacin—Headache—Sitagliptin—type 2 diabetes mellitus	0.000157	0.00086	CcSEcCtD
Solifenacin—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000155	0.000852	CcSEcCtD
Solifenacin—Angioedema—Losartan—type 2 diabetes mellitus	0.000154	0.000849	CcSEcCtD
Solifenacin—Infection—Metformin—type 2 diabetes mellitus	0.000154	0.000848	CcSEcCtD
Solifenacin—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000153	0.000841	CcSEcCtD
Solifenacin—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000152	0.000837	CcSEcCtD
Solifenacin—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000152	0.000837	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000152	0.000834	CcSEcCtD
Solifenacin—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000152	0.000834	CcSEcCtD
Solifenacin—Somnolence—Valsartan—type 2 diabetes mellitus	0.000152	0.000833	CcSEcCtD
Solifenacin—Skin disorder—Metformin—type 2 diabetes mellitus	0.000151	0.000829	CcSEcCtD
Solifenacin—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.00015	0.000826	CcSEcCtD
Solifenacin—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.00015	0.000825	CcSEcCtD
Solifenacin—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.00015	0.000825	CcSEcCtD
Solifenacin—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00015	0.000822	CcSEcCtD
Solifenacin—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.00015	0.000822	CcSEcCtD
Solifenacin—Palpitations—Losartan—type 2 diabetes mellitus	0.000149	0.000821	CcSEcCtD
Solifenacin—Nausea—Glimepiride—type 2 diabetes mellitus	0.000149	0.000818	CcSEcCtD
Solifenacin—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000148	0.000816	CcSEcCtD
Solifenacin—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000148	0.000815	CcSEcCtD
Solifenacin—Asthenia—Glyburide—type 2 diabetes mellitus	0.000148	0.000815	CcSEcCtD
Solifenacin—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000148	0.000815	CcSEcCtD
Solifenacin—Cough—Losartan—type 2 diabetes mellitus	0.000148	0.00081	CcSEcCtD
Solifenacin—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000147	0.00081	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000147	0.000809	CcSEcCtD
Solifenacin—Fatigue—Valsartan—type 2 diabetes mellitus	0.000147	0.000808	CcSEcCtD
Solifenacin—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000147	0.000806	CcSEcCtD
Solifenacin—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000147	0.000805	CcSEcCtD
Solifenacin—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000147	0.000805	CcSEcCtD
Solifenacin—Pruritus—Glyburide—type 2 diabetes mellitus	0.000146	0.000804	CcSEcCtD
Solifenacin—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000146	0.000802	CcSEcCtD
Solifenacin—Constipation—Valsartan—type 2 diabetes mellitus	0.000146	0.000801	CcSEcCtD
Solifenacin—Infection—Irbesartan—type 2 diabetes mellitus	0.000146	0.0008	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000146	0.0008	CcSEcCtD
Solifenacin—Fatigue—Orlistat—type 2 diabetes mellitus	0.000145	0.000798	CcSEcCtD
Solifenacin—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000145	0.000796	CcSEcCtD
Solifenacin—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000144	0.00079	CcSEcCtD
Solifenacin—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000144	0.00079	CcSEcCtD
Solifenacin—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.000143	0.000786	CcSEcCtD
Solifenacin—Rash—Bromocriptine—type 2 diabetes mellitus	0.000143	0.000784	CcSEcCtD
Solifenacin—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000142	0.000783	CcSEcCtD
Solifenacin—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000142	0.000782	CcSEcCtD
Solifenacin—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000142	0.00078	CcSEcCtD
Solifenacin—Headache—Bromocriptine—type 2 diabetes mellitus	0.000142	0.000779	CcSEcCtD
Solifenacin—Dry mouth—Losartan—type 2 diabetes mellitus	0.000141	0.000773	CcSEcCtD
Solifenacin—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.000139	0.000766	CcSEcCtD
Solifenacin—Confusional state—Losartan—type 2 diabetes mellitus	0.000139	0.000764	CcSEcCtD
Solifenacin—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000139	0.000763	CcSEcCtD
Solifenacin—Somnolence—Metformin—type 2 diabetes mellitus	0.000138	0.000759	CcSEcCtD
Solifenacin—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000138	0.000758	CcSEcCtD
Solifenacin—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000138	0.000757	CcSEcCtD
Solifenacin—Infection—Losartan—type 2 diabetes mellitus	0.000137	0.000753	CcSEcCtD
Solifenacin—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.000137	0.000752	CcSEcCtD
Solifenacin—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000137	0.000751	CcSEcCtD
Solifenacin—Urticaria—Valsartan—type 2 diabetes mellitus	0.000136	0.000745	CcSEcCtD
Solifenacin—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000135	0.000743	CcSEcCtD
Solifenacin—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000135	0.000742	CcSEcCtD
Solifenacin—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000135	0.000741	CcSEcCtD
Solifenacin—Tachycardia—Losartan—type 2 diabetes mellitus	0.000135	0.00074	CcSEcCtD
Solifenacin—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000134	0.000738	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000134	0.000737	CcSEcCtD
Solifenacin—Fatigue—Metformin—type 2 diabetes mellitus	0.000134	0.000736	CcSEcCtD
Solifenacin—Urticaria—Orlistat—type 2 diabetes mellitus	0.000134	0.000736	CcSEcCtD
Solifenacin—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000133	0.000732	CcSEcCtD
Solifenacin—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000133	0.000732	CcSEcCtD
Solifenacin—Constipation—Metformin—type 2 diabetes mellitus	0.000133	0.00073	CcSEcCtD
Solifenacin—Angioedema—Ramipril—type 2 diabetes mellitus	0.000132	0.000728	CcSEcCtD
Solifenacin—Vomiting—Glyburide—type 2 diabetes mellitus	0.000131	0.000722	CcSEcCtD
Solifenacin—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000131	0.000722	CcSEcCtD
Solifenacin—Rash—Glyburide—type 2 diabetes mellitus	0.00013	0.000716	CcSEcCtD
Solifenacin—Somnolence—Irbesartan—type 2 diabetes mellitus	0.00013	0.000716	CcSEcCtD
Solifenacin—Dermatitis—Glyburide—type 2 diabetes mellitus	0.00013	0.000716	CcSEcCtD
Solifenacin—Headache—Glyburide—type 2 diabetes mellitus	0.00013	0.000712	CcSEcCtD
Solifenacin—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000129	0.000709	CcSEcCtD
Solifenacin—Palpitations—Ramipril—type 2 diabetes mellitus	0.000128	0.000704	CcSEcCtD
Solifenacin—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000128	0.000703	CcSEcCtD
Solifenacin—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000127	0.0007	CcSEcCtD
Solifenacin—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000127	0.000698	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000127	0.000695	CcSEcCtD
Solifenacin—Cough—Ramipril—type 2 diabetes mellitus	0.000126	0.000695	CcSEcCtD
Solifenacin—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000126	0.000694	CcSEcCtD
Solifenacin—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.000126	0.000691	CcSEcCtD
Solifenacin—Constipation—Irbesartan—type 2 diabetes mellitus	0.000125	0.000689	CcSEcCtD
Solifenacin—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.000124	0.000682	CcSEcCtD
Solifenacin—Urticaria—Metformin—type 2 diabetes mellitus	0.000123	0.000678	CcSEcCtD
Solifenacin—Nausea—Glyburide—type 2 diabetes mellitus	0.000123	0.000675	CcSEcCtD
Solifenacin—Abdominal pain—Metformin—type 2 diabetes mellitus	0.000123	0.000675	CcSEcCtD
Solifenacin—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000123	0.000675	CcSEcCtD
Solifenacin—Somnolence—Losartan—type 2 diabetes mellitus	0.000123	0.000674	CcSEcCtD
Solifenacin—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000123	0.000673	CcSEcCtD
Solifenacin—Asthenia—Valsartan—type 2 diabetes mellitus	0.000122	0.000672	CcSEcCtD
Solifenacin—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000121	0.000667	CcSEcCtD
Solifenacin—Asthenia—Orlistat—type 2 diabetes mellitus	0.000121	0.000664	CcSEcCtD
Solifenacin—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000121	0.000664	CcSEcCtD
Solifenacin—Pruritus—Valsartan—type 2 diabetes mellitus	0.000121	0.000663	CcSEcCtD
Solifenacin—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000121	0.000663	CcSEcCtD
Solifenacin—Decreased appetite—Losartan—type 2 diabetes mellitus	0.00012	0.000659	CcSEcCtD
Solifenacin—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.00012	0.000659	CcSEcCtD
Solifenacin—Confusional state—Ramipril—type 2 diabetes mellitus	0.000119	0.000655	CcSEcCtD
Solifenacin—Pruritus—Orlistat—type 2 diabetes mellitus	0.000119	0.000655	CcSEcCtD
Solifenacin—Fatigue—Losartan—type 2 diabetes mellitus	0.000119	0.000654	CcSEcCtD
Solifenacin—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.000118	0.00065	CcSEcCtD
Solifenacin—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000118	0.000649	CcSEcCtD
Solifenacin—Constipation—Losartan—type 2 diabetes mellitus	0.000118	0.000648	CcSEcCtD
Solifenacin—Rash—Gliclazide—type 2 diabetes mellitus	0.000117	0.000643	CcSEcCtD
Solifenacin—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000117	0.000643	CcSEcCtD
Solifenacin—Urticaria—Irbesartan—type 2 diabetes mellitus	0.000116	0.00064	CcSEcCtD
Solifenacin—Headache—Gliclazide—type 2 diabetes mellitus	0.000116	0.000639	CcSEcCtD
Solifenacin—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000116	0.000637	CcSEcCtD
Solifenacin—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.000116	0.000637	CcSEcCtD
Solifenacin—Tachycardia—Ramipril—type 2 diabetes mellitus	0.000115	0.000634	CcSEcCtD
Solifenacin—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000115	0.000631	CcSEcCtD
Solifenacin—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000114	0.000625	CcSEcCtD
Solifenacin—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.000113	0.00062	CcSEcCtD
Solifenacin—Dizziness—Valsartan—type 2 diabetes mellitus	0.000113	0.00062	CcSEcCtD
Solifenacin—Dizziness—Orlistat—type 2 diabetes mellitus	0.000111	0.000612	CcSEcCtD
Solifenacin—Asthenia—Metformin—type 2 diabetes mellitus	0.000111	0.000612	CcSEcCtD
Solifenacin—Nausea—Gliclazide—type 2 diabetes mellitus	0.00011	0.000606	CcSEcCtD
Solifenacin—Pruritus—Metformin—type 2 diabetes mellitus	0.00011	0.000604	CcSEcCtD
Solifenacin—Urticaria—Losartan—type 2 diabetes mellitus	0.00011	0.000602	CcSEcCtD
Solifenacin—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000109	0.000599	CcSEcCtD
Solifenacin—Vomiting—Valsartan—type 2 diabetes mellitus	0.000108	0.000596	CcSEcCtD
Solifenacin—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.000108	0.000593	CcSEcCtD
Solifenacin—Rash—Valsartan—type 2 diabetes mellitus	0.000108	0.000591	CcSEcCtD
Solifenacin—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000107	0.00059	CcSEcCtD
Solifenacin—Vomiting—Orlistat—type 2 diabetes mellitus	0.000107	0.000589	CcSEcCtD
Solifenacin—Headache—Valsartan—type 2 diabetes mellitus	0.000107	0.000587	CcSEcCtD
Solifenacin—Rash—Orlistat—type 2 diabetes mellitus	0.000106	0.000584	CcSEcCtD
Solifenacin—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000106	0.000583	CcSEcCtD
Solifenacin—Headache—Orlistat—type 2 diabetes mellitus	0.000106	0.00058	CcSEcCtD
Solifenacin—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000105	0.000578	CcSEcCtD
Solifenacin—Somnolence—Ramipril—type 2 diabetes mellitus	0.000105	0.000578	CcSEcCtD
Solifenacin—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000104	0.000572	CcSEcCtD
Solifenacin—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000104	0.00057	CcSEcCtD
Solifenacin—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000103	0.000565	CcSEcCtD
Solifenacin—Dizziness—Metformin—type 2 diabetes mellitus	0.000103	0.000564	CcSEcCtD
Solifenacin—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000102	0.000561	CcSEcCtD
Solifenacin—Fatigue—Ramipril—type 2 diabetes mellitus	0.000102	0.00056	CcSEcCtD
Solifenacin—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.000102	0.000558	CcSEcCtD
Solifenacin—Nausea—Valsartan—type 2 diabetes mellitus	0.000101	0.000557	CcSEcCtD
Solifenacin—Constipation—Ramipril—type 2 diabetes mellitus	0.000101	0.000556	CcSEcCtD
Solifenacin—Nausea—Orlistat—type 2 diabetes mellitus	0.0001	0.00055	CcSEcCtD
Solifenacin—Asthenia—Losartan—type 2 diabetes mellitus	9.9e-05	0.000544	CcSEcCtD
Solifenacin—Vomiting—Metformin—type 2 diabetes mellitus	9.88e-05	0.000543	CcSEcCtD
Solifenacin—Rash—Metformin—type 2 diabetes mellitus	9.79e-05	0.000538	CcSEcCtD
Solifenacin—Dermatitis—Metformin—type 2 diabetes mellitus	9.78e-05	0.000538	CcSEcCtD
Solifenacin—Pruritus—Losartan—type 2 diabetes mellitus	9.76e-05	0.000536	CcSEcCtD
Solifenacin—Feeling abnormal—Ramipril—type 2 diabetes mellitus	9.75e-05	0.000536	CcSEcCtD
Solifenacin—Headache—Metformin—type 2 diabetes mellitus	9.73e-05	0.000535	CcSEcCtD
Solifenacin—Dizziness—Irbesartan—type 2 diabetes mellitus	9.69e-05	0.000533	CcSEcCtD
Solifenacin—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	9.67e-05	0.000531	CcSEcCtD
Solifenacin—Urticaria—Ramipril—type 2 diabetes mellitus	9.4e-05	0.000516	CcSEcCtD
Solifenacin—Abdominal pain—Ramipril—type 2 diabetes mellitus	9.35e-05	0.000514	CcSEcCtD
Solifenacin—Vomiting—Irbesartan—type 2 diabetes mellitus	9.32e-05	0.000512	CcSEcCtD
Solifenacin—Rash—Irbesartan—type 2 diabetes mellitus	9.24e-05	0.000508	CcSEcCtD
Solifenacin—Dermatitis—Irbesartan—type 2 diabetes mellitus	9.23e-05	0.000507	CcSEcCtD
Solifenacin—Nausea—Metformin—type 2 diabetes mellitus	9.23e-05	0.000507	CcSEcCtD
Solifenacin—Headache—Irbesartan—type 2 diabetes mellitus	9.18e-05	0.000505	CcSEcCtD
Solifenacin—Dizziness—Losartan—type 2 diabetes mellitus	9.12e-05	0.000501	CcSEcCtD
Solifenacin—Vomiting—Losartan—type 2 diabetes mellitus	8.77e-05	0.000482	CcSEcCtD
Solifenacin—Hypersensitivity—Ramipril—type 2 diabetes mellitus	8.72e-05	0.000479	CcSEcCtD
Solifenacin—Nausea—Irbesartan—type 2 diabetes mellitus	8.71e-05	0.000478	CcSEcCtD
Solifenacin—Rash—Losartan—type 2 diabetes mellitus	8.7e-05	0.000478	CcSEcCtD
Solifenacin—Dermatitis—Losartan—type 2 diabetes mellitus	8.69e-05	0.000478	CcSEcCtD
Solifenacin—Headache—Losartan—type 2 diabetes mellitus	8.64e-05	0.000475	CcSEcCtD
Solifenacin—Asthenia—Ramipril—type 2 diabetes mellitus	8.49e-05	0.000466	CcSEcCtD
Solifenacin—Pruritus—Ramipril—type 2 diabetes mellitus	8.37e-05	0.00046	CcSEcCtD
Solifenacin—Nausea—Losartan—type 2 diabetes mellitus	8.19e-05	0.00045	CcSEcCtD
Solifenacin—Dizziness—Ramipril—type 2 diabetes mellitus	7.82e-05	0.00043	CcSEcCtD
Solifenacin—Vomiting—Ramipril—type 2 diabetes mellitus	7.52e-05	0.000413	CcSEcCtD
Solifenacin—Rash—Ramipril—type 2 diabetes mellitus	7.46e-05	0.00041	CcSEcCtD
Solifenacin—Dermatitis—Ramipril—type 2 diabetes mellitus	7.45e-05	0.000409	CcSEcCtD
Solifenacin—Headache—Ramipril—type 2 diabetes mellitus	7.41e-05	0.000407	CcSEcCtD
Solifenacin—Nausea—Ramipril—type 2 diabetes mellitus	7.03e-05	0.000386	CcSEcCtD
Solifenacin—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	8.18e-06	0.000115	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	8.18e-06	0.000115	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	8.18e-06	0.000115	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.12e-06	0.000114	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PPP2CA—type 2 diabetes mellitus	8.09e-06	0.000114	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.02e-06	0.000113	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	8.02e-06	0.000113	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	8e-06	0.000112	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	7.95e-06	0.000112	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—GNB3—type 2 diabetes mellitus	7.92e-06	0.000111	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	7.92e-06	0.000111	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—GNB3—type 2 diabetes mellitus	7.85e-06	0.00011	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	7.84e-06	0.00011	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	7.84e-06	0.00011	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MMP3—type 2 diabetes mellitus	7.82e-06	0.00011	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AVP—type 2 diabetes mellitus	7.82e-06	0.00011	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	7.81e-06	0.00011	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IGF2—type 2 diabetes mellitus	7.78e-06	0.000109	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	7.77e-06	0.000109	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—MTHFR—type 2 diabetes mellitus	7.77e-06	0.000109	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	7.75e-06	0.000109	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AVP—type 2 diabetes mellitus	7.74e-06	0.000109	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MMP3—type 2 diabetes mellitus	7.74e-06	0.000109	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IGF2—type 2 diabetes mellitus	7.71e-06	0.000108	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	7.69e-06	0.000108	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	7.69e-06	0.000108	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.68e-06	0.000108	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—INS—type 2 diabetes mellitus	7.68e-06	0.000108	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	7.67e-06	0.000108	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	7.67e-06	0.000108	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PPARA—type 2 diabetes mellitus	7.62e-06	0.000107	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	7.59e-06	0.000107	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	7.58e-06	0.000106	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.56e-06	0.000106	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APOB—type 2 diabetes mellitus	7.55e-06	0.000106	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	7.55e-06	0.000106	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	7.52e-06	0.000106	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APOB—type 2 diabetes mellitus	7.48e-06	0.000105	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.46e-06	0.000105	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	7.45e-06	0.000105	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.43e-06	0.000104	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.43e-06	0.000104	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.43e-06	0.000104	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.4e-06	0.000104	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AGT—type 2 diabetes mellitus	7.38e-06	0.000104	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EDN1—type 2 diabetes mellitus	7.36e-06	0.000103	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—INS—type 2 diabetes mellitus	7.36e-06	0.000103	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—CALM1—type 2 diabetes mellitus	7.26e-06	0.000102	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.24e-06	0.000102	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	7.24e-06	0.000102	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—APOE—type 2 diabetes mellitus	7.23e-06	0.000102	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—LPL—type 2 diabetes mellitus	7.21e-06	0.000101	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	7.2e-06	0.000101	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—APOA1—type 2 diabetes mellitus	7.15e-06	0.0001	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—LPL—type 2 diabetes mellitus	7.14e-06	0.0001	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.12e-06	0.0001	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.11e-06	9.99e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.08e-06	9.95e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.08e-06	9.95e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.06e-06	9.92e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.06e-06	9.92e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	6.99e-06	9.82e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	6.96e-06	9.77e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	6.96e-06	9.77e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	6.96e-06	9.77e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	6.96e-06	9.77e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.79e-06	9.54e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.77e-06	9.51e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.76e-06	9.5e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.74e-06	9.47e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.74e-06	9.47e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	6.7e-06	9.42e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	6.67e-06	9.37e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.67e-06	9.37e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.65e-06	9.34e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCR5—type 2 diabetes mellitus	6.58e-06	9.25e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	6.51e-06	9.15e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—C3—type 2 diabetes mellitus	6.49e-06	9.12e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.45e-06	9.07e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.45e-06	9.07e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—C3—type 2 diabetes mellitus	6.43e-06	9.04e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—RELA—type 2 diabetes mellitus	6.34e-06	8.91e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PPARG—type 2 diabetes mellitus	6.3e-06	8.85e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.21e-06	8.73e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	6.2e-06	8.71e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.2e-06	8.71e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.19e-06	8.7e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	6.19e-06	8.7e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.18e-06	8.68e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—INS—type 2 diabetes mellitus	6.18e-06	8.68e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	6.17e-06	8.67e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.13e-06	8.62e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.12e-06	8.6e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	6.11e-06	8.58e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.09e-06	8.55e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—RELA—type 2 diabetes mellitus	6.07e-06	8.53e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.07e-06	8.52e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	6.06e-06	8.52e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	6.06e-06	8.52e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	6.05e-06	8.49e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	6.05e-06	8.49e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.01e-06	8.44e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	6e-06	8.42e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	5.99e-06	8.41e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	5.99e-06	8.41e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.98e-06	8.4e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	5.92e-06	8.32e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	5.79e-06	8.13e-05	CbGpPWpGaD
Solifenacin—CHRM4—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.77e-06	8.11e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.72e-06	8.04e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.72e-06	8.04e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.7e-06	8.01e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.68e-06	7.99e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	5.67e-06	7.97e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	5.67e-06	7.97e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	5.66e-06	7.96e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	5.65e-06	7.93e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	5.56e-06	7.81e-05	CbGpPWpGaD
Solifenacin—CHRM5—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.53e-06	7.77e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	5.53e-06	7.76e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	5.53e-06	7.76e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	5.53e-06	7.76e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	5.49e-06	7.72e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.48e-06	7.7e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.44e-06	7.65e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	5.42e-06	7.61e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	5.42e-06	7.61e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.41e-06	7.6e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.41e-06	7.6e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	5.39e-06	7.58e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.39e-06	7.58e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.35e-06	7.52e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	5.34e-06	7.5e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	5.33e-06	7.49e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.24e-06	7.37e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	5.18e-06	7.28e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.18e-06	7.27e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	5.16e-06	7.26e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.12e-06	7.2e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	5.11e-06	7.19e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.1e-06	7.16e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.08e-06	7.14e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.03e-06	7.07e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.02e-06	7.06e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.01e-06	7.04e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.01e-06	7.04e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	5e-06	7.02e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.99e-06	7.01e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.99e-06	7.01e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—SRC—type 2 diabetes mellitus	4.98e-06	7e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.97e-06	6.98e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	4.96e-06	6.96e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	4.96e-06	6.96e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	4.96e-06	6.96e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	4.95e-06	6.96e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.95e-06	6.95e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.94e-06	6.95e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4.92e-06	6.92e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	4.86e-06	6.83e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.85e-06	6.82e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	4.82e-06	6.77e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—SRC—type 2 diabetes mellitus	4.77e-06	6.71e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.76e-06	6.69e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.74e-06	6.67e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	4.72e-06	6.63e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	4.7e-06	6.6e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.65e-06	6.53e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.54e-06	6.38e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.54e-06	6.38e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	4.53e-06	6.37e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.53e-06	6.36e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.53e-06	6.36e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.49e-06	6.3e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.49e-06	6.3e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	4.48e-06	6.3e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	4.48e-06	6.3e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.46e-06	6.26e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.37e-06	6.14e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	4.3e-06	6.04e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	4.3e-06	6.04e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	4.28e-06	6.01e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.27e-06	6e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	4.26e-06	5.99e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	4.22e-06	5.93e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.18e-06	5.88e-05	CbGpPWpGaD
Solifenacin—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.89e-06	5.47e-05	CbGpPWpGaD
Solifenacin—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.88e-06	5.45e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.86e-06	5.42e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.85e-06	5.4e-05	CbGpPWpGaD
Solifenacin—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.84e-06	5.4e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.83e-06	5.38e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.82e-06	5.37e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.81e-06	5.35e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.78e-06	5.32e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	3.7e-06	5.2e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.7e-06	5.2e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	3.69e-06	5.18e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.65e-06	5.12e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	3.64e-06	5.11e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.63e-06	5.11e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.61e-06	5.07e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.6e-06	5.06e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.6e-06	5.05e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.56e-06	5e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.54e-06	4.97e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.53e-06	4.96e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.52e-06	4.95e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.49e-06	4.9e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	3.44e-06	4.83e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.37e-06	4.74e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	3.36e-06	4.72e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—IL6—type 2 diabetes mellitus	3.36e-06	4.72e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	3.35e-06	4.71e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	3.32e-06	4.66e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.3e-06	4.64e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.29e-06	4.62e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.27e-06	4.6e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.26e-06	4.58e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.23e-06	4.54e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—IL6—type 2 diabetes mellitus	3.22e-06	4.52e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.2e-06	4.5e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.16e-06	4.44e-05	CbGpPWpGaD
Solifenacin—CHRM4—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.1e-06	4.35e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.04e-06	4.27e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3e-06	4.22e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.99e-06	4.21e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	2.98e-06	4.18e-05	CbGpPWpGaD
Solifenacin—CHRM5—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.97e-06	4.17e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.97e-06	4.17e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.95e-06	4.14e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.94e-06	4.13e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.91e-06	4.09e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	2.88e-06	4.05e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	2.84e-06	3.99e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	2.83e-06	3.97e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	2.79e-06	3.93e-05	CbGpPWpGaD
Solifenacin—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	2.49e-06	3.5e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.46e-06	3.46e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.41e-06	3.39e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.26e-06	3.18e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	2.26e-06	3.17e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.23e-06	3.14e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.21e-06	3.11e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.12e-06	2.98e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.12e-06	2.98e-05	CbGpPWpGaD
Solifenacin—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.09e-06	2.93e-05	CbGpPWpGaD
Solifenacin—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.08e-06	2.93e-05	CbGpPWpGaD
Solifenacin—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.06e-06	2.9e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	1.94e-06	2.72e-05	CbGpPWpGaD
Solifenacin—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	9.73e-07	1.37e-05	CbGpPWpGaD
